USSTOCK.TODAY
Regular Market
Log in Sign up

FDA Approves Teva's Monthly Olanzapine Injection for Schizophrenia

Pharmaceutical Technology ·

TEVA Teva- Pharmaceutical Industries Ltd
$40.21 -1.01%
View chart & analysis →
  1. 1The FDA has approved Teva's monthly olanzapine injection for the treatment of schizophrenia.
  2. 2Teva plans to provide Weltruza in 318mg, 425mg, and 531mg doses within weeks.
  3. 3Relink Partners estimated Weltruza's expected revenue at $1.3 billion in 2026.

So what's the key point?

The U.S. Food and Drug Administration has authorized Teva's once-a-month injection for schizophrenia. Relink Partners expects this medication to generate $1.3 billion in revenue in 2026.

Source Pharmaceutical Technology · View original ↗

Related 3-line summaries

Teva Pharmaceutical Industries Receives FDA Approval for Schizophrenia Treatment Nasdaq +2 · Oct 9Nine Mid-Size Drugmakers Agree to Cut Prices, Invest $19.6B in U.S. Factories Stocktwits +1 · Sep 1Trump expands drug pricing deal to 26 companies, adding 9 more Barrons.com +1 · Sep 1
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news